PL3426244T3 - Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania - Google Patents

Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania

Info

Publication number
PL3426244T3
PL3426244T3 PL17764038.0T PL17764038T PL3426244T3 PL 3426244 T3 PL3426244 T3 PL 3426244T3 PL 17764038 T PL17764038 T PL 17764038T PL 3426244 T3 PL3426244 T3 PL 3426244T3
Authority
PL
Poland
Prior art keywords
dehydrogenase inhibitors
phosphoglycerate dehydrogenase
phosphoglycerate
inhibitors
dehydrogenase
Prior art date
Application number
PL17764038.0T
Other languages
English (en)
Inventor
Nello Mainolfi
Original Assignee
Raze Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raze Therapeutics, Inc. filed Critical Raze Therapeutics, Inc.
Publication of PL3426244T3 publication Critical patent/PL3426244T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
PL17764038.0T 2016-03-09 2017-03-08 Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania PL3426244T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305940P 2016-03-09 2016-03-09
PCT/US2017/021436 WO2017156179A1 (en) 2016-03-09 2017-03-08 3-phosphoglycerate dehydrogenase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
PL3426244T3 true PL3426244T3 (pl) 2023-09-25

Family

ID=59789712

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17764038.0T PL3426244T3 (pl) 2016-03-09 2017-03-08 Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania

Country Status (5)

Country Link
US (3) US11014882B2 (pl)
EP (2) EP4234552A3 (pl)
ES (1) ES2949357T3 (pl)
PL (1) PL3426244T3 (pl)
WO (1) WO2017156179A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
DK3426243T3 (da) 2016-03-09 2021-07-19 Raze Therapeutics Inc 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
CN111909040A (zh) * 2019-05-10 2020-11-10 南京莱克施德药业有限公司 一种Elagolix中间体2-氟-6-三氟甲基苄胺的制备方法
WO2021173962A1 (en) * 2020-02-28 2021-09-02 Genemo, Inc. Methods and materials for diagnosis and treatment of neuronal disorder
CN115867315A (zh) * 2020-04-07 2023-03-28 理论科学公司 用于抑制细胞外囊泡的分泌的细胞外囊泡分泌抑制剂及其用途
CN116981656B (zh) 2021-03-17 2025-09-26 三井化学株式会社 锂(n-羰基)磺酰胺化合物、锂二次电池用添加剂、锂二次电池用非水电解液、锂二次电池前体、锂二次电池、及锂二次电池的制造方法
WO2024126453A1 (en) 2022-12-15 2024-06-20 Boehringer Ingelheim International Gmbh New substituted indole-2-carboxamides as phgdh inhibitors
EP4637757A1 (en) 2022-12-19 2025-10-29 Chiesi Farmaceutici S.p.A. Phosphoglicerate dehydrogenase inhibitors for the treatment of fibrosis
CN117603123B (zh) * 2023-11-04 2026-03-13 郑州大学 新型吲哚类hdac6小分子抑制剂、制备方法和应用
WO2025125295A1 (en) 2023-12-13 2025-06-19 Chiesi Farmaceutici S.P.A. Thieno-indole amide derivatives as phgdh inhibitors
WO2025125293A1 (en) 2023-12-13 2025-06-19 Chiesi Farmaceutici S.P.A. Thienopyrimidylamine derivatives as phgdh inhibitors
WO2025125292A1 (en) 2023-12-13 2025-06-19 Chiesi Farmaceutici S.P.A. New phosphoglicerate dehydrogenase inhibitors for the treatment of fibrosis
WO2025233465A1 (en) 2024-05-10 2025-11-13 Chiesi Farmaceutici S.P.A. Process and intermediates for the preparation of a phosphoglicerate dehydrogenase inhibitor
WO2025233464A1 (en) 2024-05-10 2025-11-13 Chiesi Farmaceutici S.P.A. Process and intermediates for the preparation of a phosphoglicerate dehydrogenase inhibitor

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US5639600A (en) 1994-08-05 1997-06-17 The Regents Of The University Of California Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
WO2000042213A1 (en) 1999-01-13 2000-07-20 The Research Foundation Of State University Of New York A novel method for designing protein kinase inhibitors
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
AR034897A1 (es) 2001-08-07 2004-03-24 Hoffmann La Roche Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
WO2003035621A1 (en) 2001-10-22 2003-05-01 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
WO2006067445A2 (en) 2004-12-22 2006-06-29 Astrazeneca Ab Csf-1r kinase inhibitors
CN101128454A (zh) 2004-12-22 2008-02-20 阿斯利康(瑞典)有限公司 用作抗癌药物的吡啶羧酰胺衍生物
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20100168102A9 (en) * 2005-07-11 2010-07-01 Devgen Nv Amide Derivatives as Kinase Inhibitors
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
DK1910384T3 (da) 2005-08-04 2012-12-17 Sirtris Pharmaceuticals Inc Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
KR20090024115A (ko) * 2006-04-12 2009-03-06 에프. 호프만-라 로슈 아게 5-아미도-2-카복스아마이드 인돌
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
US7838542B2 (en) * 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
BRPI0718677A2 (pt) 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
MX2009012678A (es) * 2007-05-25 2012-09-20 Vertex Pharma Moduladores de canal de ion y metodos de uso.
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
ES2647317T3 (es) * 2008-11-03 2017-12-20 Syntarga B.V. Análogos de CC-1065 y sus conjugados
US9096579B2 (en) * 2012-04-20 2015-08-04 Boehringer Ingelheim International Gmbh Amino-indolyl-substituted imidazolyl-pyrimidines and their use as medicaments
WO2014184235A1 (en) * 2013-05-15 2014-11-20 Acturum Life Science AB Benzamide trpa1 antagonists
US10167257B2 (en) * 2014-04-04 2019-01-01 Iomet Pharma Ltd. Indole derivatives for use in medicine
DK3426243T3 (da) 2016-03-09 2021-07-19 Raze Therapeutics Inc 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
EP4234552A3 (en) 2016-03-09 2023-10-18 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof

Also Published As

Publication number Publication date
US20220017464A1 (en) 2022-01-20
US12264132B2 (en) 2025-04-01
EP3426244B1 (en) 2023-06-07
ES2949357T3 (es) 2023-09-28
US11014882B2 (en) 2021-05-25
EP3426244C0 (en) 2023-06-07
EP4234552A2 (en) 2023-08-30
EP3426244A4 (en) 2019-11-06
US20190071400A1 (en) 2019-03-07
WO2017156179A1 (en) 2017-09-14
US11535593B2 (en) 2022-12-27
EP3426244A1 (en) 2019-01-16
US20230348386A1 (en) 2023-11-02
EP4234552A3 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
PL3426244T3 (pl) Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
IL280863A (en) Autotaxin inhibitors and uses thereof
IL282090A (en) Tyk2 inhibitors and uses thereof
IL269196A (en) Novel inhibitors
DK3658557T3 (da) Tyk2-inhibitorer og anvendelser deraf
PL3500564T3 (pl) Inhibitory acylotransferazy diacyloglicerolu 2
PL3468966T3 (pl) Inhibitory interakcji menina-mll
EP3526222A4 (en) TYK2 INHIBITORS AND THEIR USES
EP3528816A4 (en) TYK2 INHIBITORS AND USES THEREOF
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
IL283106A (en) Erk inhibitors and uses thereof
DK3497086T3 (da) Aminopyrimidin-SSAO-inhibitorer
DK3442972T3 (da) Bromdomænehæmmere
DK3277681T3 (da) Imidazolonylquinoliner og deres anvendelse som atm-kinaseinhibitorer
DK3571192T3 (da) Jak1-selektive inhibitorer
LT3303334T (lt) Tirozinkinazės inhibitoriai
PL3509591T3 (pl) Nowe selektywne inhibitory Jak1 i ich zastosowanie
DK3426243T3 (da) 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf
EP3386505A4 (en) AZA-BENZIMIDAZOLINHIBITORS OF PAD4
PL3157534T3 (pl) Inhibitory acetylocholinesteraz w leczeniu stanów dermatologicznych
DK3341379T3 (da) EZH2-hæmmere
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3630744T3 (da) Pyrazol-magl-inhibitorer
EP3720436A4 (en) TUBULIN INHIBITORS